chronic hepatitis B

Functional Cure Within Reach: GSK’s Bepirovirsen Meets Primary Endpoints in Pivotal Phase III Chronic Hepatitis B Trials

By MedXY 01/07/2026

GSK has announced positive Phase III results for Bepirovirsen, an antisense oligonucleotide that achieves functional cure in chronic hepatitis B patients. By targeting viral RNA and HBsAg, the drug offers a finite treatment path, potentially transforming global hepatology standards and replacing lifelong therapy.

Clinical Updates Infectious Diseases news

Elebsiran Combined with Pegylated Interferon Alfa for Chronic Hepatitis B: Advances from Phase 2 Clinical Trials

By MedXY 11/13/2025

Phase 2 studies demonstrate that elebsiran, a small interfering RNA, combined with PEG-IFNα, enhances sustained HBsAg loss rates in chronic HBV infection, offering a promising approach toward functional cure.

Clinical Updates Infectious Diseases news Specialties

Sequential Pegylated Interferon after Bepirovirsen Lowers Relapse Risk in Chronic Hepatitis B: Insights from the B-Together Trial

By MedXY 09/20/2025

The B-Together phase IIb study demonstrates that sequential therapy with bepirovirsen followed by pegylated interferon-α-2a reduces post-treatment relapse in chronic hepatitis B patients on stable nucleos(t)ide analogue therapy, with enhanced responses in patients with lower baseline HBsAg levels.